Anti-CD19 chimeric antigen receptor T cell therapy - Aleta Biotherapeutics

Drug Profile

Anti-CD19 chimeric antigen receptor T cell therapy - Aleta Biotherapeutics

Alternative Names: CAR-CD19 T cells; CD19-anti-HER2-scFv; CD19-anti-HER2-scFv FP

Latest Information Update: 02 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Aleta Biotherapeutics
  • Class Antineoplastics; CAR-T cell therapies
  • Mechanism of Action CD19 antigen modulators; Cytotoxic T lymphocyte stimulants; ERBB 2 receptor modulators; Gene transference; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Acute lymphoblastic leukaemia; Non-Hodgkin's lymphoma

Most Recent Events

  • 01 Apr 2017 Preclinical trials in Acute lymphoblastic leukaemia in USA (Parenteral)
  • 01 Apr 2017 Preclinical trials in Non-Hodgkin's lymphoma in USA (Parenteral)
  • 01 Apr 2017 Pharmacodynamics data from a preclinical trial in Acute lymphocytic leukaemia and Non-Hodgkin lymphoma presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top